Committed to a Healthier and Happier World
Transasia Bio-Medicals Ltd. has been providing quality, affordable diagnostic solutions for over three decades to over 35,000 pathology laboratories in India and in over 110 countries all over the world.
A simpler strategy of AIM – Affordability and Accessibility, Innovation, and Make in India continue to remain our roadmap in becoming India’s leading in vitro diagnostic company. Transasia plays a major role in impacting lives through wider accessibility and greater affordability. Transasia is the only company in India to have an extensive sales and services network supporting both governmental and private labs in over 300 Tier I–IV cities and towns of India. To achieve broader coverage, Transasia also has a network of 350 channel partners.
By adopting cutting edge technology from our 14 overseas subsidiaries and customizing it to cater to the Indian market, we are able to provide innovative solutions.
Transasia was the first Indian diagnostic company to manufacture the world’s latest technologies in India. By doing so, we have been able to leverage on the advantages of low-cost production to meet the domestic needs. We now boast of over 65,000 installations across 35,000 labs in India.
Having said that we continue to focus on inorganic and organic growth in an effort to serve the emerging markets. Over the past 2 years we have acquired Erba Molecular, UK (formerly known as Lumora) and Calbiotech, USA. Both these companies bring to the table expertise in introducing novel technologies in molecular testing and immunoassays respectively. Besides this, our latest manufacturing hub at Sikkim along with the ones at Baddi, Daman, and Mumbai will further strengthen our Make in India capabilities.
Amongst our recent launches, the ErbaQik range of rapid tests with unique features for accurate dengue and malaria detection is an endeavor to contain the spread of these diseases in 2018. Besides this, ECL 760, our latest coagulation analyzer employs technology from our European subsidiary and is three times faster and comes at a cost that is 30 percent lesser compared to imported analyzers from leading global companies. Laura XL is the most recent technological advancement for affordable urinalysis. It allows sediment testing by microscopy, simulated using artificial intelligence combined with digital microscopy. Artificial intelligence automatically recognizes the sediment element resulting in fast and accurate classification and quantitative determination of sediment content.
Going forward, we plan to keep the focus on technology through our global R&D especially in the fields of immunology and molecular diagnostics. We will continue to focus on timeless ELISA and IFAs, while introducing newer platforms like chemiluminescence immunoassay (CLIA). On the other hand, in the field of molecular testing, Transasia is working on combining special technology that makes molecular diagnostics less complex and introduce products that are customized to Indian needs. Nex-gen sequencing is another growing trend we are adopting as a preferred method of choice for detection of TB, dengue, malaria, chikungunya, etc. in India, so that these diseases can be treated faster with products that are affordable and accessible.
In 2018, Transasia and ERBA group are planning to launch several new, advanced diagnostic systems and will further consolidate our #1 position in the Indian IVD industry.
